Literature DB >> 16099380

STAT3-mediated activation of myocardial capillary growth.

Denise Hilfiker-Kleiner1, Anne Limbourg, Helmut Drexler.   

Abstract

Proper perfusion and vessel integrity are key requisites for myocardial homeostasis. In this regard, myocardial angiogenesis occurs in physiologic and pathologic conditions. Failure in this process and the resulting deficient oxygen supply induce loss and degeneration of cardiomyocytes, atrophy, and interstitial fibrosis and are viewed as a primary cause of myocardial dysfunction and heart failure. In this review, signal transducer and activator of transcription 3 (STAT3) is highlighted as a regulator of proangiogenic circuits promoting vessel formation in the adult heart under physiologic and pathophysiologic conditions. Specifically, STAT3 regulates proangiogenic vascular endothelial growth factor (VEGF) expression and activity in the postnatal heart and suppresses an antiangiogenic and profibrotic gene program by controlling autocrine and paracrine circuits. In addition, signaling through STAT3 represents a necessary survival pathway for cardiomyocytes and endothelial cells and seems to promote cytokine-mediated cardiac angiogenesis. In contrast, STAT3 seems not to be required for differentiation processes of embryonic or adult endothelial progenitor cells. In summary, the properly timed expression and activation of STAT3 play a critical role on cardiac angiogenesis and involve the subtle control of paracrine and autocrine mechanisms regulating angiogenic circuits and survival pathways of cardiomyocytes and endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16099380     DOI: 10.1016/j.tcm.2005.05.002

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  21 in total

1.  Erythropoietin and ventricular remodelling: a VEGF-dependent neovascularity.

Authors:  Tariq Hamid; Sumanth D Prabhu
Journal:  Cardiovasc Res       Date:  2010-05-05       Impact factor: 10.787

2.  Interleukin-10 deficiency impairs bone marrow-derived endothelial progenitor cell survival and function in ischemic myocardium.

Authors:  Prasanna Krishnamurthy; Melissa Thal; Suresh Verma; Eneda Hoxha; Erin Lambers; Veronica Ramirez; Gangjian Qin; Douglas Losordo; Raj Kishore
Journal:  Circ Res       Date:  2011-09-29       Impact factor: 17.367

Review 3.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

Authors:  Thomas Force; Kyle L Kolaja
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

4.  Association between polymorphisms in the signal transducer and activator of transcription and dilated cardiomyopathy in the Chinese Han population.

Authors:  Ying Peng; Bin Zhou; Yanyun Wang; Yu Chen; Hui Li; Yaping Song; Lin Zhang; Li Rao
Journal:  Mol Cell Biochem       Date:  2011-09-23       Impact factor: 3.396

5.  The JAK/STAT3 signalling pathway regulated angiogenesis in an endothelial cell/adipose-derived stromal cell co-culture, 3D gel model.

Authors:  Changyue Xue; Jiamin Xie; Dan Zhao; Shiyu Lin; Tengfei Zhou; Sirong Shi; Xiaoru Shao; Yunfeng Lin; Bofeng Zhu; Xiaoxiao Cai
Journal:  Cell Prolif       Date:  2016-09-25       Impact factor: 6.831

6.  Exogenous IL-19 attenuates acute ischaemic injury and improves survival in male mice with myocardial infarction.

Authors:  Weishuai An; Yongsheng Yu; Yuefan Zhang; Zhigang Zhang; Yunhua Yu; Xianxian Zhao
Journal:  Br J Pharmacol       Date:  2019-01-08       Impact factor: 8.739

7.  Suppressors of cytokine-signaling proteins induce insulin resistance in the retina and promote survival of retinal cells.

Authors:  Xuebin Liu; Marie G Mameza; Yun Sang Lee; Chikezie I Eseonu; Cheng-Rong Yu; Jennifer J Kang Derwent; Charles E Egwuagu
Journal:  Diabetes       Date:  2008-03-20       Impact factor: 9.461

8.  HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy.

Authors:  Manuela Bartoli; Mohamed Al-Shabrawey; Mohamed Labazi; M Ali Behzadian; Mohamed Istanboli; Azza B El-Remessy; Robert W Caldwell; Dennis M Marcus; Ruth B Caldwell
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-12-20       Impact factor: 4.799

Review 9.  Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.

Authors:  Ming Hui Chen; Risto Kerkelä; Thomas Force
Journal:  Circulation       Date:  2008-07-01       Impact factor: 29.690

Review 10.  Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem.

Authors:  Thomas Force; Risto Kerkelä
Journal:  Drug Discov Today       Date:  2008-09-02       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.